Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin in CD30+ Cutaneous T-Cell Lymphoma
NCT01578499Phase 3Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Jun 2012
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of brentuximab vedotin in mycosis fungoides (MF), primary cutaneous anaplastic large cell lymphoma (PCALCL), sponsored by Millennium Pharmaceuticals. Started Jun 2012; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
mycosis fungoides (MF)primary cutaneous anaplastic large cell lymphoma (PCALCL)
Beyond the preview
Go deeper on NCT01578499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01578499.